RECOMMENDATIONS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ( MASH) DISEASE MANAGEMENT: A MODIFIED DELPHI PANEL

被引：0
|
作者：
Watzker, Anna [1 ]
Delegge, Mark [2 ]
Fernandes, Gail [1 ]
Melaragno, Matthew [1 ]
Williams, Rhys [2 ]
Godinho, Fatima [2 ]
Drymaliti, Kyriaki [2 ]
Engel, Samuel [1 ]
机构：
[1] Merck & Co Inc, Rahway, NJ USA
[2] IQVIA, Durham, NC USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1730
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Thyroid hormone receptor-b analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
    Ratziu, Vlad
    Scanlan, Thomas S.
    Bruinstroop, Eveline
    JOURNAL OF HEPATOLOGY, 2025, 82 (02) : 375 - 387
  • [22] UNVEILING THE HIDDEN CONNECTION: EXPLORING THE INTERPLAY BETWEEN PERICARDITIS AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
    Ramirez, Lisnaldy
    Garzon-Siatoya, Wendy
    Aloum, Khalid
    Forlemu, Arnold Nongmoh
    Bandaru, Praneeth
    Ciobanu, Camelia
    Wakil, Ali
    Forlemu, Raissa Nana Sede Mbakop
    Krishna, Vura Naga Venkata Rama
    Sharma, Neha
    HEPATOLOGY, 2024, 80 : S472 - S472
  • [23] ECONOMIC COST OF INACTION FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN GERMANY, JAPAN, AND THE UNITED STATES
    Younossi, Zobair
    Tacke, Frank
    Schattenberg, Joern
    Roden, Michael
    Lazarus, Jeffrey
    Allen, Alina
    Cusi, Kenneth
    Eguchi, Yuichiro
    Takahashi, Hirokazu
    Kawaguchi, Takumi
    Wong, Vincent
    Mark, Henry
    Brachowicz, Nicolai
    Henry, Linda
    Nader, Fatema
    Paik, James
    HEPATOLOGY, 2024, 80 : S816 - S817
  • [24] IMPACT OF FIBROSIS SEVERITY ON CLINICAL AND METAGENOMIC PROFILES IN MASH (METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS) PATIENTS
    Joung, Hyunchae
    Joo, Jaeryang
    Kim, KyungHwan
    Shin, Chang Hun
    Lee, Hye Won
    HEPATOLOGY, 2024, 80 : S788 - S789
  • [25] EXTRACELLULAR VESICLES AS A THERAPY FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND HEPATOCELLULAR CARCINOMA (HCC)
    Goonetilleke, M.
    Correia, J.
    Chen, Y.
    McDonald, H.
    Chan, S. T.
    Simpson, I.
    Inocencio, I. M.
    Sievert, W.
    Lim, R.
    CYTOTHERAPY, 2024, 26 (06) : S75 - S76
  • [26] Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States
    Younossi, Zobair
    Lazarus, Jeffrey V.
    Allen, Alina M.
    Cusi, Kenneth
    Tacke, Frank
    Roden, Michael
    Schattenberg, Jorn M.
    Mark, Henry E.
    Henry, Linda
    Nader, Fatema
    Paik, James M.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S470 - S471
  • [27] Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH)
    Younossi, Zobair
    Stepanova, Maria
    Younossi, Issah
    Racila, Andrei
    JOURNAL OF HEPATOLOGY, 2024, 80 : S101 - S102
  • [28] Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes
    Shah, A.
    Mohammadi, A.
    Haq, A.
    Walji, D.
    Zevin, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2025, 73 (01) : 297 - 299
  • [29] Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis
    Li, Xincheng
    Ayada, Ibrahim
    Li, Pengfei
    Pan, Qiuwei
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 108 - 109
  • [30] Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
    Francque, Sven M.
    Vonghia, Luisa
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (12): : 1066 - 1067
12345